{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04407247",
            "orgStudyIdInfo": {
                "id": "2019-0276"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2019-04986",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "2019-0276",
                    "type": "OTHER",
                    "domain": "M D Anderson Cancer Center"
                }
            ],
            "organization": {
                "fullName": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma",
            "officialTitle": "Treatment of Immune Checkpoint Inhibitor-Related Colitis With Infliximab or Vedolizumab: A Randomized Trial",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Gastroenterology"
            ],
            "study": "infliximab-or-vedolizumab-in-treating-immune-checkpoint-inhibitor-related-colitis-in-patients-with-genitourinary-cancer-or-melanoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2020-07-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-05-27",
            "studyFirstSubmitQcDate": "2020-05-27",
            "studyFirstPostDateStruct": {
                "date": "2020-05-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-01",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This phase I/II trial studies the side effects of infliximab and vedolizumab and to see how well they work in treating inflammation of the colon (colitis) caused by immune checkpoint inhibitor therapy in patients with cancer of the genital and urinary organs (genitourinary) or melanoma. Monoclonal antibodies, such as infliximab or vedolizumab, may help to treat immunotherapy induced colitis/diarrhea. This study may help to identify the optimal treatment strategy for immune checkpoint inhibitor-related colitis in patients with genitourinary cancer or melanoma.",
            "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. To compare the efficacy of infliximab and vedolizumab for clinical remission/response of immune-related diarrhea and/or colitis.\n\nII. To assess the safety and tolerability of the treatment for immune-mediated diarrhea and/or colitis.\n\nSECONDARY OBJECTIVES:\n\nI. To assess the efficacy of infliximab and vedolizumab for clinical remission/response of IMC at 4 weeks.\n\nII. To assess the success of corticosteroid tapering. III. To measure the recurrence rate after corticosteroid taper.\n\nEXPLORATORY OBJECTIVES:\n\nI. To assess the efficacy of infliximab and vedolizumab to achieve endoscopic remission of immune-related diarrhea and/or colitis.\n\nII. To assess the efficacy of infliximab and vedolizumab to achieve histological remission of immune-related diarrhea and/or colitis.\n\nIII. To assess the time duration to achieve the clinical remission/response. IV. To assess the long term outcome of cancer. V. To assess immunological, molecular and microbiome changes in tissue/blood/stool.\n\nOUTLINE: Patients are randomized to 1 of 2 arms.\n\nARM I: Patients receive infliximab intravenously (IV) over 1 hour once at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.\n\nARM II: Patients receive vedolizumab IV over 1 hour once at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.\n\nPatients are followed up weekly for 1 month and then at 2 and 3 months after the treatment."
        },
        "conditionsModule": {
            "conditions": [
                "Colitis",
                "Lung Non-Small Cell Carcinoma",
                "Malignant Genitourinary System Neoplasm",
                "Malignant Solid Neoplasm",
                "Melanoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm I (infliximab)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Patients receive infliximab IV over 1 hour once at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.",
                    "interventionNames": [
                        "Biological: Infliximab"
                    ]
                },
                {
                    "label": "Arm II (vedolizumab)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients receive vedolizumab IV over 1 hour at week 0, 2, 6 for a total of 3 doses in the absence of disease progression or unacceptable toxicity.",
                    "interventionNames": [
                        "Biological: Vedolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Infliximab",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Arm I (infliximab)"
                    ],
                    "otherNames": [
                        "Avakine",
                        "cA2",
                        "Remicade",
                        "Remsima"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Vedolizumab",
                    "description": "Given IV",
                    "armGroupLabels": [
                        "Arm II (vedolizumab)"
                    ],
                    "otherNames": [
                        "Entyvio",
                        "Immunoglobulin G1, anti-(human integrin LPAM-1 (lymphocyte Peyer''s patch adhesion molecule 1)) (human-Mus musculus heavy chain), disulfide with human-Mus musculus kappa-chain, dimer",
                        "LDP 02",
                        "LDP-02",
                        "LDP02",
                        "MLN0002",
                        "MLN02"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Clinical remission/response rate of immune-mediated colitis (IMC)",
                    "description": "The difference of the remission rate between standard of care (infliximab + corticosteroid) and the treatment with vedolizumab + corticosteroid will be calculated along with the 95% confidence interval.",
                    "timeFrame": "At 2 weeks after initiation of infliximab or vedolizumab with corticosteroid taper"
                },
                {
                    "measure": "Treatment-related adverse events",
                    "description": "Will follow standard reporting guidelines for adverse events. Safety data will be summarized by category, severity and frequency.",
                    "timeFrame": "Within 3 months after initiation of infliximab or vedolizumab"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Clinical remission/response rate of IMC",
                    "description": "Will be estimated and compared between the two treatment arms using chi-square test.",
                    "timeFrame": "At 4 weeks after initiation of infliximab or vedolizumab with corticosteroid taper"
                },
                {
                    "measure": "Complete weaning of corticosteroid",
                    "description": "Will be estimated and compared between the two treatment arms using chi-square test.",
                    "timeFrame": "Within 4 weeks after infliximab or vedolizumab initiation without rebound of IMC"
                },
                {
                    "measure": "Recurrent immune-related diarrhea/colitis",
                    "description": "Will be estimated and compared between the two treatment arms using chi-square test.",
                    "timeFrame": "Within 3 months after corticosteroid taper"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Endoscopic remission (Mayo Clinic sub-score 0-1) of immune-related diarrhea/colitis",
                    "description": "Will be compared between the two treatment arms.",
                    "timeFrame": "At 4 and 8 weeks after initiation of infliximab or vedolizumab treatment"
                },
                {
                    "measure": "Histological remission (resolution of active inflammation) of immune-related diarrhea/colitis",
                    "description": "Will be compared between the two treatment arms.",
                    "timeFrame": "At 8 weeks after initiation of infliximab or vedolizumab treatment"
                },
                {
                    "measure": "Time duration to achieve clinical remission/response",
                    "description": "Will be estimated using the method of Kaplan and Meier. Comparisons of the time-to-event endpoint by important subgroups will be made using the log-rank tests.",
                    "timeFrame": "From initiation of infliximab or vedolizumab treatment to clinical remission/response or last follow-up, assessed up to 3 months"
                },
                {
                    "measure": "Overall survival",
                    "description": "Will be estimated using the method of Kaplan and Meier.",
                    "timeFrame": "From the initiation of infliximab or vedolizumab treatment till death or last follow-up, assessed up to 3 months"
                },
                {
                    "measure": "Change in levels of cytokines in tissue/blood/stool samples",
                    "description": "Will be compared using 2-sample t-test.",
                    "timeFrame": "Baseline up to 3 months after infliximab or vedolizumab treatment"
                },
                {
                    "measure": "Change in frequencies of immune cells in tissue/blood/stool samples",
                    "description": "Will be compared using 2-sample t-test.",
                    "timeFrame": "Baseline up to 3 months after infliximab or vedolizumab treatment"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who receive any type of immune checkpoint inhibitor (ICI) therapy\n* Patients with peak grade \\>= 2 immune-related diarrhea and/or colitis (according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 within 45 days prior to initiation of study treatment (infliximab/ vedolizumab)\n* Patients with ability to understand and willingness to sign informed consent\n* Patients with genitourinary cancer or melanoma or non-small cell lung cancer\n* No concern for active concomitant GI infection for immune-related diarrhea and/or colitis work up at the time of protocol therapy initiation as confirmed by stool tests or as per the treating physician based on clinical presentation\n* Patient who has been cleared for enrollment by Infectious Diseases consultant or treating physician if positive infection workup or screening tests (e.g. lifelong positive T-spot due to BCG inoculation, chronic colonization) prior to initiation of diarrhea/colitis treatment\n\nExclusion Criteria:\n\n* Patients younger than 18 years of age\n* Patients with persistent gastrointestinal infection confirmed with positive testing despite completing 5 days of antibiotics\n* Patients are on concurrent immunosuppressive therapies other than what will be given for colitis\n* Patients with preexisting activehistory of inflammatory bowel disease and/or radiation enterocolitis with active disease status at the time of study treatment initiation\n* Pregnant and breastfeeding women, and\n* Women of child-bearing potential who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was \\> 1 year prior to consent and/ or clear documentation states that patient is peri- or post-menopausal or there was recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to initiation of study treatment\n* Patients who develop concurrent non-GI toxicity at the time of study treatment initiation",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Yinghong Wang",
                    "role": "CONTACT",
                    "phone": "713-792-7672",
                    "email": "ywang59@mdanderson.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Yinghong Wang",
                    "affiliation": "M.D. Anderson Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "M D Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Yinghong Wang",
                            "role": "CONTACT",
                            "phone": "713-792-7672"
                        },
                        {
                            "name": "Yinghong Wang",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "MD Anderson Cancer Center",
                    "url": "http://www.mdanderson.org"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008545",
                    "term": "Melanoma"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                },
                {
                    "id": "D000003092",
                    "term": "Colitis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                },
                {
                    "id": "D000018326",
                    "term": "Nevi and Melanomas"
                },
                {
                    "id": "D000012878",
                    "term": "Skin Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000005759",
                    "term": "Gastroenteritis"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000003108",
                    "term": "Colonic Diseases"
                },
                {
                    "id": "D000007410",
                    "term": "Intestinal Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Lung Non-Small Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M6320",
                    "name": "Colitis",
                    "asFound": "Colitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "asFound": "Melanoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12448",
                    "name": "Nevus, Pigmented",
                    "relevance": "LOW"
                },
                {
                    "id": "M12446",
                    "name": "Nevus",
                    "relevance": "LOW"
                },
                {
                    "id": "M20470",
                    "name": "Nevi and Melanomas",
                    "relevance": "LOW"
                },
                {
                    "id": "M15681",
                    "name": "Skin Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8875",
                    "name": "Gastroenteritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6336",
                    "name": "Colonic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10444",
                    "name": "Intestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000069285",
                    "term": "Infliximab"
                },
                {
                    "id": "C000543529",
                    "term": "Vedolizumab"
                },
                {
                    "id": "D000007136",
                    "term": "Immunoglobulins"
                },
                {
                    "id": "D000007074",
                    "term": "Immunoglobulin G"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000079424",
                    "term": "Tumor Necrosis Factor Inhibitors"
                },
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000003879",
                    "term": "Dermatologic Agents"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M11541",
                    "name": "Melphalan",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "asFound": "Eligible",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10122",
                    "name": "Immunoglobulin G",
                    "asFound": "Kcal",
                    "relevance": "HIGH"
                },
                {
                    "id": "M288641",
                    "name": "Vedolizumab",
                    "asFound": "ASD",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19117",
                    "name": "Immunoglobulins, Intravenous",
                    "relevance": "LOW"
                },
                {
                    "id": "M375",
                    "name": "Infliximab",
                    "asFound": "Day 2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M2052",
                    "name": "Tumor Necrosis Factor Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7074",
                    "name": "Dermatologic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                }
            ]
        }
    },
    "hasResults": false
}